Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Cross Below 200-Day Moving Average – Here’s Why

by · The Cerbat Gem

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $31.10 and traded as low as $28.21. Lakefront Biotherapeutics American Depositary Shares shares last traded at $28.37, with a volume of 125,293 shares.

Wall Street Analyst Weigh In

LKFT has been the subject of a number of recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. UBS Group reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, February 24th. Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Zacks Research raised shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Finally, Wall Street Zen downgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.50.

View Our Latest Research Report on LKFT

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -20.07 and a beta of 0.26. The business’s 50 day moving average price is $28.16 and its 200 day moving average price is $31.08.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) last posted its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The firm had revenue of $1.06 billion during the quarter. Sell-side analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several hedge funds have recently modified their holdings of LKFT. ABC Arbitrage SA purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at about $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Lakefront Biotherapeutics American Depositary Shares during the first quarter worth approximately $248,000. QRG Capital Management Inc. grew its holdings in Lakefront Biotherapeutics American Depositary Shares by 21.9% in the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock valued at $591,000 after purchasing an additional 3,535 shares during the period. XTX Topco Ltd grew its holdings in Lakefront Biotherapeutics American Depositary Shares by 92.6% in the fourth quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock valued at $759,000 after purchasing an additional 11,162 shares during the period. Finally, Millennium Management LLC increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 121.9% in the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after buying an additional 186,452 shares in the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

(Get Free Report)

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.

Featured Articles